Pharmanutra Balance Sheet Health
Financial Health criteria checks 5/6
Pharmanutra has a total shareholder equity of €58.9M and total debt of €24.5M, which brings its debt-to-equity ratio to 41.6%. Its total assets and total liabilities are €115.6M and €56.7M respectively. Pharmanutra's EBIT is €26.9M making its interest coverage ratio 19.8. It has cash and short-term investments of €17.8M.
Key information
41.6%
Debt to equity ratio
€24.48m
Debt
| Interest coverage ratio | 19.8x |
| Cash | €17.82m |
| Equity | €58.90m |
| Total liabilities | €56.70m |
| Total assets | €115.60m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 761's short term assets (€63.4M) exceed its short term liabilities (€28.1M).
Long Term Liabilities: 761's short term assets (€63.4M) exceed its long term liabilities (€28.6M).
Debt to Equity History and Analysis
Debt Level: 761's net debt to equity ratio (11.3%) is considered satisfactory.
Reducing Debt: 761's debt to equity ratio has increased from 19.2% to 41.6% over the past 5 years.
Debt Coverage: 761's debt is well covered by operating cash flow (93.4%).
Interest Coverage: 761's interest payments on its debt are well covered by EBIT (19.8x coverage).